Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study

Autor: Jonge, M.M. de, Kroon, C.D. de, Jenner, D.J., Oosting, J., Hullu, J.A. de, Mourits, M.J.E., Garcia, E.B.G., Ausems, M.G.E.M., Collee, J.M., Engelen, K. van, Beek, I. van de, Group, H., Smit, V.T.H.B.M., Rookus, M.A., Bock, G.H. de, Leeuwen, F.E. van, Bosse, T., Dekkers, O.M., Asperen, C.J. van

Publikováno v: Journal of the National Cancer Institute, 113(9), 1203-1211. Oxford University Press
Journal of the National Cancer Institute, 113(9):djab036, 1203-1211. Oxford University Press
Journal of the National Cancer Institute, 113, 9, pp. 1203-1211
Hebon Group 2021, ' Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations : Multicenter Cohort Study ', Journal of the National Cancer Institute, vol. 113, no. 9, pp. 1203-1211 . https://doi.org/10.1093/jnci/djab036
Journal of the National Cancer Institute, 113(9), 1203-1211. OXFORD UNIV PRESS INC
JNCI Journal of the National Cancer Institute
Journal of the National Cancer Institute, 113, 1203-1211

Background Endometrial cancer (EC) risk in BReast CAncer gene 1/2 (BRCA1/2) mutation carriers is uncertain; therefore, we assessed this in a large Dutch nationwide cohort study. Methods We selected 5980 BRCA1/2 (3788 BRCA1, 2151 gBRCA2, 41 both BRCA1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2a8791550eac2799958c465080935b7
https://pure.amc.nl/en/publications/endometrial-cancer-risk-in-women-with-germline-brca1-or-brca2-mutations(da798180-cfc5-4b4e-8433-751f87d7bc99).html

Clinicopathological and Molecular Specificities of Inflammatory Bowel Disease–Related Colorectal Neoplastic Lesions: The Role of Inflammation.

Autor: Svrcek, Magali, Nunes, Paula Borralho, Villanacci, Vincenzo, Beaugerie, Laurent, Rogler, Gerhard, Hertogh, Gert De, Tripathi, Monika, Feakins, Roger, group, H-ECCO

Publikováno v: Journal of Crohn's & Colitis; Dec2018, Vol. 12 Issue 12, p1486-1498, 13p

The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug?

Autor: Puoti, Massimo, COZZI LEPRI, A, Ancarani, F, Bruno, R, Ambu, S, Ferraro, T, Tundo, P, Santantonio, T, Toti, M, Bonasso, M, D'ARMINIO MONFORTE, A, CONA STUDY GROUP, H. E. P. A. I., ICONA STUDY GROUP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3662::9dbe1411cdd0bb638128103c76eaf4ba
http://hdl.handle.net/11379/21413

Results of the RIST experiment to design a high power target for the production of radioactive nuclear beams.

Autor: Densham, C. J., Bennett, J. R. J., Burridge, R. A., Broome, T. A., Drumm, P., Evans, W. R., Gardner, I. S. K., Holding, M., McPherson, G. M., Murdoch, G. R., Panteleev, V., Walker, T. G., Aitken, T. W., Kay, J., Metcalf, S., Price, H., Warner, D. D., Ravn and the ISOLDE Group, H.

Publikováno v: AIP Conference Proceedings; Feb1997, Vol. 392 Issue 1, p377-380, 4p

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals

Autor: Antonucci, G, Girardi, E, COZZI LEPRI, A, Capobianchi, Mr, DE LUCA, A, Puoti, Massimo, Petrelli, E, Carnevale, G, Rizzardini, G, Grossi, Pa, Vigano, P, Moioli, Mc, Carletti, F, Solmone, M, Ippolito, G, Monforte, Ad, STUDY GROUP, H. E. P. A. I. C. O. N. A., ITALIAN COHORT NAIVE FOR ANTIRETROVIRALS STUDY GROUP

Publikováno v: Scopus-Elsevier

Background. The roles of hepatitis C virus (HCV) viremia and HCV genotype in the immune response to highly active antiretroviral therapy (HAART) are poorly understood. Our aim was to assess the CD4(+) cell count recovery after HAART in human immunode

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c5d22c7c4a8bfc908beb329e6ef8c1d
http://www.scopus.com/inward/record.url?eid=2-s2.0-33644519208&partnerID=MN8TOARS